VYANT BIO
Vyant Bio, Inc. (“Vyant Bio” or “Company”) operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company is executing on the integration of these two leading businesses to integrate human-powered scientific and technology-based systems and expertise with years of preclinical experience to de-risk and accelerate discovery and development of preclinical and clinical pipelines for biopharma partners as well as for the proprietary pipeline of the Company.
VYANT BIO
Industry:
Biotechnology Genetics Health Care Health Diagnostics Oncology
Founded:
1999-01-01
Address:
Rutherford, New Jersey, United States
Country:
United States
Website Url:
http://www.vyantbio.com
Total Employee:
51+
Status:
Active
Contact:
+112015289200
Email Addresses:
[email protected]
Total Funding:
48.24 M USD
Technology used in webpage:
Amazon COVID-19 Amazon Sydney Region CenturyLink
Similar Organizations
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Bluebird Bio
Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Castle Biosciences
Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
Human Longevity
Human Longevity is a genomic-based, health intelligence company empowering proactive healthcare and enabling a life better lived.
Instadiagnostics
Instadiagnostics Inc., is developing a rapid, quantitative, point-of-care (POC) diagnostic platform.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Aspira Women's Health
Aspira Women's Health develops and commercializes diagnostic tests that address unmet needs in gynecologic oncology and women’s health.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-03-31 | StemoniX | StemoniX acquired by Vyant Bio | N/A |
| 2020-08-24 | StemoniX | StemoniX acquired by Vyant Bio | 12.6 M USD |
| 2017-08-14 | vivoPharm | vivoPharm acquired by Vyant Bio | 12 M USD |
| 2015-08-10 | Response Genetics Inc. | Response Genetics Inc. acquired by Vyant Bio | 14 M USD |
| 2014-08-18 | BioServe Biotechnologies (India) | BioServe Biotechnologies (India) acquired by Vyant Bio | 1.9 M USD |
| 2014-07-21 | Gentris | Gentris acquired by Vyant Bio | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-26 | Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief Scientific Officer |
Official Site Inspections
http://www.vyantbio.com Semrush global rank: 8.22 M Semrush visits lastest month: 601
- Host name: 11.158.123.34.bc.googleusercontent.com
- IP address: 34.123.158.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vyant Bio"
Reaction Biology and Vyant Bio Announce Closing of
Nov 3, 2022 Vyant Bio, Inc. (“Vyant Bio” or the “Company”) (Nasdaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and …See details»
Reaction Biology and Vyant Bio Announce Closing of Definitive …
Nov 3, 2022 Founded in 2001, Reaction is a contract research organization (CRO) that has provided drug discovery and development services to more than 1,800 biopharmaceutical …See details»
Vyant Bio - Crunchbase Company Profile & Funding
Vyant Bio, Inc. (“Vyant Bio” or “Company”) operates two wholly-owned subsidiaries, StemoniX and vivoPharm. The Company is executing on the integration of these two leading businesses …See details»
Vyant Bio Company Profile 2024: Valuation, Funding & Investors
Vyant Bio is headquartered in Cherry Hill, NJ. What is the size of Vyant Bio? Vyant Bio has 85 total employees. What industry is Vyant Bio in? Vyant Bio’s primary industry is Biotechnology. …See details»
Vyant Bio, Inc. - AnnualReports.com
Vyant Bio, Inc. is a leader in drug discovery and preclinical oncology and immuno-oncology services enhancing the development of advanced therapies in …See details»
Reaction Biology and Vyant Bio Announce Closing of Definitive …
Nov 3, 2022 ~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~ ~ Transaction Expands Reaction Biology’s …See details»
Vyant Bio - LinkedIn
Vyant Bio | 9,590 followers on LinkedIn. Uniting Human biology, engineering, data science, and passion to transform lives | Vyant Bio (Nasdaq: VYNT) - uniting human biology, engineering, data ...See details»
Vyant Bio Announces Stockholder Approval of Plan of Dissolution
Nov 1, 2023 At the Special Meeting, Vyant Bio’s stockholders, upon the unanimous recommendation of Vyant Bio’s board of directors, voted in favor of the proposal to approve …See details»
Vyant Bio Reports Third Quarter 2021 Results and Provides …
Nov 11, 2021 Strategic Highlights Hired Robert Fremeau, Jr., PhD as Chief Scientific Officer to lead Vyant Bio’s R&D programs targeting the identification of novel therapeuticsEntered into …See details»
Vyant Bio Announces Newly Appointed Board of Directors
CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered …See details»
Vyant Bio advancing plan to be a 'pure play' biotech …
Mar 30, 2022 “Vyant Bio is committed to transforming into a pure-play drug discovery and development biotech company," said Robert T. Fremeau, the company’s chief scientific officer. The company has 14 ...See details»
Vyant Bio (NASD: VYNT) is on the Cutting Edge of Biotech Drug ...
Mar 23, 2022 Vyant Bio’s current focus is working on two rare diseases — CDKL5 deficiency disorder and Rett Syndrome. CDKL5 deficiency disorder affects primarily female infants. …See details»
Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief
Oct 26, 2021 We are looking forward to having Dr. Fremeau work across the Vyant Bio organization with colleagues and partners in translational biology, chemical sciences, and …See details»
Vyant Bio Announces Robert T. Fremeau, Jr. Ph.D. as Chief …
Oct 26, 2021 We are looking forward to having Dr. Fremeau work across the Vyant Bio organization with colleagues and partners in translational biology, chemical sciences, and …See details»
Press Release - VivoPharm
Nov 3, 2022 Founded in 2001, Reaction is a contract research organization (CRO) that has provided drug discovery and development services to more than 1,800 biopharmaceutical …See details»
Transforming drug discovery to get more breakthrough medicines …
Vyant Bio has also moved into cancer R&D, using rich genetic data, AI-assisted protein-design models, and the cell-line assets and oncology expertise from a collaboration partner and its ...See details»
Vyant Bio Presents Key Takeaways from Platform and Poster
Nov 16, 2022 Vyant Bio’s management believes that drug discovery needs to progressively shift to more efficient methods as the widely used models for predicting safe and effective drugs …See details»
Vyant Bio and OrganoTherapeutics Announce Strategic …
Mar 29, 2022 Robert Fremeau, PhD, Vyant Bio’s Chief Scientific Officer, states “This collaboration with OrganoTherapeutics is another example of Vyant Bio’s commitment to …See details»
Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and …
Mar 30, 2022 Vyant Bio filed its Year-End 2021 on Form 10-K today with the Securities and Exchange Commission. Please refer to Vyant Bio’s Form 10-K for more detailed information …See details»
Vyant Bio and OrganoTherapeutics Announce Strategic
Mar 29, 2022 Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets and novel and …See details»